Heterologous RBMRNA-405 mRNA booster enhances humoral immunity post-inactivated COVID-19 vaccination: a randomized clinical trial in adults and older through 12 months

Abstract To address the urgent need for effective immunization strategies against SARS-CoV-2 variants, particularly in older adults who are more vulnerable to severe disease, we evaluated the safety and immunogenicity of the bivalent COVID-19 mRNA vaccine RBMRNA-405 as a third-dose booster in adults...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Xiaolan Yong, Jianxing He, Caroline Zhang, Yongji Wang, Yoko Ou, Biliang Zhang
Format:	Artigo
Język:	Inglês
Wydane:	Nature Portfolio 2026-03-01
Seria:	Scientific Reports
Hasła przedmiotowe:	COVID-19 vaccine mRNA vaccine Heterologous boost Safety Immunogenicity Older adults
Dostęp online:	https://doi.org/10.1038/s41598-026-45429-w
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!